{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T05:57:47Z","timestamp":1782626267854,"version":"3.54.5"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T00:00:00Z","timestamp":1565136000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T00:00:00Z","timestamp":1565136000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000062","name":"NIDDK","doi-asserted-by":"crossref","award":["2U01-DK065179-06"],"award-info":[{"award-number":["2U01-DK065179-06"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000062","name":"NIDDK","doi-asserted-by":"crossref","award":["2U01-DK065201-06"],"award-info":[{"award-number":["2U01-DK065201-06"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000062","name":"NIDDK","doi-asserted-by":"crossref","award":["2U01-DK065184-06"],"award-info":[{"award-number":["2U01-DK065184-06"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000062","name":"NIDDK","doi-asserted-by":"crossref","award":["2U01-DK065211-06"],"award-info":[{"award-number":["2U01-DK065211-06"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000062","name":"NIDDK","doi-asserted-by":"crossref","award":["1U01-DK083020-01"],"award-info":[{"award-number":["1U01-DK083020-01"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s12072-019-09971-2","type":"journal-article","created":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T13:02:56Z","timestamp":1565182976000},"page":"641-648","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Asparaginase-induced hepatotoxicity: rapid development of cholestasis and hepatic steatosis"],"prefix":"10.1007","volume":"13","author":[{"name":"for the Drug-Induced Liver Injury Network","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Kamal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niharika","family":"Samala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Stolz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Durazo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul H.","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongrong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay H.","family":"Hoofnagle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,7]]},"reference":[{"key":"9971_CR1","doi-asserted-by":"publisher","first-page":"62","DOI":"10.4103\/0976-500X.184769","volume":"7","author":"RA Egler","year":"2016","unstructured":"Egler RA, Ahuja SP, Matloub Y. l-asparaginase in the treatment of patients with acute lymphoblastic leukemia. J Pharmacol Pharmacother 2016;7:62\u201371","journal-title":"J Pharmacol Pharmacother"},{"key":"9971_CR2","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1097\/MPH.0b013e3181e6f003","volume":"32","author":"EA Raetz","year":"2010","unstructured":"Raetz EA, Salzer WL. Tolerability and efficacy of l-asparaginase therapy in pediatric patients with acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2010;32:554\u2013563","journal-title":"J Pediatr Hematol Oncol"},{"key":"9971_CR3","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1126\/science.160.3827.533","volume":"160","author":"B Horowitz","year":"1968","unstructured":"Horowitz B, Madras BK, Meister A, et al. Asparagine synthetase activity of mouse leukemias. Science 1968;160:533\u2013535","journal-title":"Science"},{"key":"9971_CR4","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1084\/jem.127.6.1055","volume":"127","author":"JD Broome","year":"1968","unstructured":"Broome JD. Studies on the mechanism of tumor inhibition by l-asparaginase. Effects of the enzyme on asparagine levels in the blood, normal tissues, and 6C3HED lymphomas of mice: differences in asparagine formation and utilization in asparaginase-sensitive and -resistant lymphoma cells. J Exp Med 1968;127:1055\u20131072","journal-title":"J Exp Med"},{"key":"9971_CR5","first-page":"600","volume":"7","author":"M Earl","year":"2009","unstructured":"Earl M. Incidence and management of asparaginase-associated adverse events in patients with acute lymphoblastic leukemia. Clin Adv Hematol Oncol 2009;7:600\u2013606","journal-title":"Clin Adv Hematol Oncol"},{"issue":"2","key":"9971_CR6","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/1097-0142(197002)25:2<253::AID-CNCR2820250204>3.0.CO;2-U","volume":"25","author":"HF Oettgen","year":"1970","unstructured":"Oettgen HF, Stephenson PA, Schwartz MK, et al. Toxicity of E. Coli l-asparaginase in man. Cancer 1970;25(2):253\u2013278","journal-title":"Cancer"},{"key":"9971_CR7","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1542\/peds.45.4.555","volume":"45","author":"CG Zubrod","year":"1970","unstructured":"Zubrod CG. The clinical toxicities of l-asparaginase: in treatment of leukemia and lymphoma. Pediatrics 1970;45:555\u2013559","journal-title":"Pediatrics"},{"key":"9971_CR8","first-page":"335","volume":"4","author":"MS Cairo","year":"1982","unstructured":"Cairo MS. Adverse reactions of l-asparaginase. Am J Pediatr Hematol Oncol 1982;4:335\u2013339","journal-title":"Am J Pediatr Hematol Oncol"},{"key":"9971_CR9","doi-asserted-by":"publisher","first-page":"748","DOI":"10.3109\/10428194.2015.1101098","volume":"57","author":"N Hijiya","year":"2016","unstructured":"Hijiya N, van der Sluis IM. Asparaginase-associated toxicity in children with acute lympholastic leukemia. Leuk Lymphoma 2016;57:748\u2013757","journal-title":"Leuk Lymphoma"},{"key":"9971_CR10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.leukres.2016.08.014","volume":"50","author":"TZ Horvat","year":"2016","unstructured":"Horvat TZ, Pecoraro JJ, Daley RJ, et al. The use of Erwinia asparaginase for adult patients with acute lymphoblastic leukemia after pegaspargase intolerance. Leuk Res 2016;50:17\u201320","journal-title":"Leuk Res"},{"key":"9971_CR11","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1053\/j.gastro.2015.03.006","volume":"148","author":"N Chalasani","year":"2015","unstructured":"Chalasani N, Bonkovsky HL, Fontana R, et al. United States Drug Induced Liver Injury Network. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. Gastroenterology 2015;148:1340\u20131352","journal-title":"Gastroenterology"},{"key":"9971_CR12","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2165\/00002018-200932010-00005","volume":"32","author":"RJ Fontana","year":"2009","unstructured":"Fontana RJ, Watkins PB, Bonkovsky HL, et al. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf 2009;32:55\u201368","journal-title":"Drug Saf."},{"key":"9971_CR13","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1002\/hep.23577","volume":"51","author":"DC Rockey","year":"2010","unstructured":"Rockey DC, Seeff LB, Rochon J, et al. US Drug-Induced Liver Injury Network. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology 2010;51:2117\u20132126","journal-title":"Hepatology"},{"key":"9971_CR14","doi-asserted-by":"publisher","first-page":"30172444","DOI":"10.1371\/journal.pone.0172444","volume":"12","author":"JH Karnes","year":"2017","unstructured":"Karnes JH, Shaffer CM, Bastarache L, et al. Comparison of HLA allelic imputation programs. PLoS One 2017;12:30172444","journal-title":"PLoS One"},{"key":"9971_CR15","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1182\/blood-2014-02-558767","volume":"124","author":"L Gragert","year":"2014","unstructured":"Gragert L, Fingerson S, Albrecht M, et al. Fine-mapping of HLA associations with chronic lymphocytic leukemia in US populations. Blood 2014;124:2657\u20132665","journal-title":"Blood"},{"key":"9971_CR16","first-page":"300","volume":"3","author":"KY Urayama","year":"2013","unstructured":"Urayama KY, Thompson PD, Taylor M, et al. Genetic variation in the extended major histocompatibility complex and susceptibility to childhood acute lymphoblastic leukemia: a review of the evidence. Font Oncol 2013;3:300","journal-title":"Font Oncol"},{"key":"9971_CR17","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1182\/blood.V97.5.1211","volume":"97","author":"LB Silverman","year":"2001","unstructured":"Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood 2001;97:1211\u20131218","journal-title":"Blood"},{"key":"9971_CR18","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.leukres.2017.12.013","volume":"66","author":"PW Burke","year":"2018","unstructured":"Burke PW, Aldoss I, Lunning MA, et al. Pegaspargase-related high-grade hepatotoxicity in a pediatric-inspired adult acute lymphoblastic leukemia regimen does not predict recurrent hepatotoxicity with subsequent doses. Leuk Res 2018;66:49\u201356","journal-title":"Leuk Res"},{"key":"9971_CR19","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/1097-0142(197108)28:2<361::AID-CNCR2820280215>3.0.CO;2-3","volume":"28","author":"CB Pratt","year":"1971","unstructured":"Pratt CB, Johnson WW. Duration and severity of fatty metamorphosis of the liver following l-asparaginase therapy. Cancer 1971;28:361\u2013364","journal-title":"Cancer"},{"key":"9971_CR20","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1055\/s-2003-42647","volume":"23","author":"S Sahoo","year":"2003","unstructured":"Sahoo S, Hart J. Histopathological features of l-asparaginase-induced liver disease. Seminar Liver Dis 2003;23:295\u2013299","journal-title":"Seminar Liver Dis"},{"key":"9971_CR21","first-page":"400","volume":"98","author":"BL Webber","year":"1974","unstructured":"Webber BL, Freiman I. The liver in kwashiorkor. A clinical and electron microscopic study. Arch Pathol 1974;98:400\u2013408","journal-title":"Arch Pathol"},{"key":"9971_CR22","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1159\/000353402","volume":"59","author":"A Roesmann","year":"2013","unstructured":"Roesmann A, Afify M, Panse J, et al. l-carnitine ameliorates l-asparaginase-induced acute liver toxicity in steatotic rat livers. Chemotherapy 2013;59:167\u2013175","journal-title":"Chemotherapy"},{"key":"9971_CR23","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1159\/000442342","volume":"135","author":"R Alshiekh-Nasany","year":"2016","unstructured":"Alshiekh-Nasany R, Douer D. l-carnitine for treatment of pegaspargase-induced hepatotoxicity. Acta Haematol 2016;135:208\u2013210.","journal-title":"Acta Haematol"},{"key":"9971_CR24","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.3109\/10428194.2013.845886","volume":"55","author":"C Al-Nawakil","year":"2014","unstructured":"Al-Nawakil C, Willems L, Mauprivez C, et al. Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors. Leuk Lymphoma 2014;55:1670\u20131674","journal-title":"Leuk Lymphoma"},{"key":"9971_CR25","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1177\/1078155217710714","volume":"24","author":"A Blackman","year":"2018","unstructured":"Blackman A, Boutin A, Shimanovsky A, et al. Levocarnitine and vitamin B complex for the treatment of pegaspargase-induced hepatotoxicity: a case report and review of the literature. J Oncol Pharm Pract 2018;24:393\u2013397","journal-title":"J Oncol Pharm Pract"},{"issue":"775","key":"9971_CR26","first-page":"779","volume":"79","author":"R Jenkins","year":"1987","unstructured":"Jenkins R, Perlin E. Severe hepatotoxicity from Escherichia coli l-asparaginase. J Natl Med Assoc 1987;79(775):779","journal-title":"J Natl Med Assoc"},{"key":"9971_CR27","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1159\/000095827","volume":"74","author":"M Bodmer","year":"2006","unstructured":"Bodmer M, Sulz M, Stadlmann S. Fatal liver failure in an adult patient with acute lymphoblastic leukemia following treatment with l-asparaginase. Digestion 2006;74:28\u201332","journal-title":"Digestion"},{"key":"9971_CR28","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1111\/ejh.12600","volume":"96","author":"I Aldoss","year":"2016","unstructured":"Aldoss I, Douer D, Behrendt CE, et al. Toxicity profile of repeated doses of PEG-asparaginase incorporated into a pediatric-type regimen for adult acute lymphoblastic leukemia. Eur J Haematol 2016;96:375\u2013380","journal-title":"Eur J Haematol"},{"key":"9971_CR29","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.3109\/10428194.2011.596963","volume":"52","author":"W Stock","year":"2011","unstructured":"Stock W, Douer D, DeAngelo DJ, et al. Prevention and management of asparaginase\/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel. Leuk Lymphoma 2011;52:2237\u20132253","journal-title":"Leuk Lymphoma"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-019-09971-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12072-019-09971-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-019-09971-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,25]],"date-time":"2022-09-25T08:06:21Z","timestamp":1664093181000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12072-019-09971-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,7]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["9971"],"URL":"https:\/\/doi.org\/10.1007\/s12072-019-09971-2","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,7]]},"assertion":[{"value":"12 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Natasha Kamal has nothing to disclose. Christopher Koh has nothing to disclose. Niharika Samala has nothing to disclose. Andrew Stolz has nothing to disclose. Paul H. Hayashi has nothing to disclose. Tongrong Wang has nothing to disclose. Jay H. Hoofnagle has nothing to disclose. Francisco Durazo receives consulting fees from Intercept Pharmaceuticals. Robert J. Fontana receives grant support from Abbvie, Gilead Sciences and Bristol-Myers-Squibb and consulting fees from Sanofi-Aventis. Elizabeth Phillips receives personal fees from UpToDate and Biocryst and holds patent for HLA-B*57:01 testing for abacavir hypersensitivity without financial remuneration.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008 (5). Informed consent was obtained from all patients for being included in the study. The DILIN Prospective Study was approved by the Institutional Review Boards of the enrolling clinical centers, and all participants provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent in studies with human subjects"}}]}}